Details of the Drug Combinations

General Information of This Drug (ID: DM6OC53)

Drug Name
PDX-101   DM6OC53
Synonyms
Belinostat; 414864-00-9; PXD101; PXD-101; Belinostat (PXD101); Beleodaq; 866323-14-0; (E)-N-hydroxy-3-(3-(N-phenylsulfamoyl)phenyl)acrylamide; PXD 101; N-HYDROXY-3-(3-PHENYLSULFAMOYLPHENYL)ACRYLAMIDE; UNII-F4H96P17NZ; Belinostat(Random Configuration); NSC726630; PX105684; PX 105684; F4H96P17NZ; CHEBI:61076; (2E)-N-hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide; N-HYDROXY-3-[3-[(PHENYLAMINO)SULFONYL]PHENYL]-2-PROPENAMIDE; (E)-N-hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide; PX-105684
Indication
Disease Entry ICD 11 Status REF
Plasma cell myeloma 2A83.1 Approved [1]
Primary cutaneous peripheral T-cell lymphoma not otherwise specified N.A. Approved [1]
Primary cutaneous T-cell lymphoma N.A. Approved [1]
Solid tumour/cancer 2A00-2F9Z Phase 2 [2]
Haematological malignancy 2B33.Y Phase 1 [3]
Peripheral T-cell lymphoma 2A90.C Phase 1 [3]
⏷ Show the Full List of Indication(s)
Therapeutic Class
Anticancer Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

22 Investigative Drug Combination(s) Consisting of This drug
Normalized Drug Combination Synergy Score
Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.
DrugCom Name DrugCom ID Component Drug Indication REF
Belinostat + Panobinostat DCDOM5X Panobinostat Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [4]
Belinostat + Mitomycin DCCN4LC Mitomycin Diffuse large B cell lymphoma (Cell Line: TMD8) [4]
Belinostat + Ruxolitinib DCIKV4T Ruxolitinib Hodgkin lymphoma (Cell Line: L-1236) [5]
Belinostat + Trametinib DCWJQTU Trametinib Embryonal rhabdomyosarcoma (Cell Line: Rh36) [5]
Belinostat + Trametinib DCIQSBG Trametinib Embryonal rhabdomyosarcoma (Cell Line: RD) [5]
Belinostat + JQ1 DCLHWO2 JQ1 Embryonal rhabdomyosarcoma (Cell Line: Rh36) [5]
Belinostat + JQ1 DCI7TZR JQ1 Embryonal rhabdomyosarcoma (Cell Line: CTR) [5]
Belinostat + JQ1 DC4YRLQ JQ1 Embryonal rhabdomyosarcoma (Cell Line: RD) [5]
Belinostat + PMID25656651-Compound-5 DCZ7KXY PMID25656651-Compound-5 Embryonal rhabdomyosarcoma (Cell Line: Rh36) [5]
Belinostat + Ceritinib DCDOIVU Ceritinib Embryonal rhabdomyosarcoma (Cell Line: Rh36) [5]
Belinostat + Ceritinib DCKA0RJ Ceritinib Embryonal rhabdomyosarcoma (Cell Line: CTR) [5]
Belinostat + Ceritinib DCI6S7Z Ceritinib Embryonal rhabdomyosarcoma (Cell Line: RD) [5]
Belinostat + BMS-754807 DC284UN BMS-754807 Embryonal rhabdomyosarcoma (Cell Line: Rh36) [5]
Belinostat + BMS-754807 DCX0LF7 BMS-754807 Embryonal rhabdomyosarcoma (Cell Line: CTR) [5]
Belinostat + BMS-754807 DCGS75C BMS-754807 Embryonal rhabdomyosarcoma (Cell Line: RD) [5]
Belinostat + MK-2206 DCJE5WF MK-2206 Embryonal rhabdomyosarcoma (Cell Line: RD) [5]
Everolimus + Belinostat DCKIJUY Everolimus Embryonal rhabdomyosarcoma (Cell Line: Rh36) [4]
Everolimus + Belinostat DCXZCZL Everolimus Embryonal rhabdomyosarcoma (Cell Line: CTR) [4]
Everolimus + Belinostat DCGOM2F Everolimus Embryonal rhabdomyosarcoma (Cell Line: RD) [4]
GSK2126458 + Belinostat DCJ7Z8D GSK2126458 Embryonal rhabdomyosarcoma (Cell Line: Rh36) [5]
SCH772984 + Belinostat DCBIAM8 SCH772984 Embryonal rhabdomyosarcoma (Cell Line: Rh36) [5]
SCH772984 + Belinostat DCFFUMP SCH772984 Embryonal rhabdomyosarcoma (Cell Line: RD) [5]
------------------------------------------------------------------------------------
⏷ Show the Full List of 22 DrugCom(s)
15 Clinical Trial Drug Combination(s) Consisting of This drug
DrugCom Name DrugCom ID Component Drug Indication REF
Belinostat + Idarubicin DC0FII1 Idarubicin Acute Myeloid Leukemia [6]
Belinostat + Tanespimycin DC7DYOW Tanespimycin Adult Nasal Type Extranodal NK/T-cell Lymphoma [7]
Belinostat + Bortezomib DC8WIEL Bortezomib Acute Lymphocytic Leukemia [8]
Belinostat + Carboplatin DCDR475 Carboplatin Brenner Tumor [9]
Belinostat + Bortezomib DCFQALZ Bortezomib Adult Grade III Lymphomatoid Granulomatosis [10]
Belinostat + Azacitidine DCNJBEZ Azacitidine Accelerated Phase of Disease [11]
Belinostat + Tazemetostat DC77XDW Tazemetostat Recurrent B-Cell Non-Hodgkin Lymphoma [12]
Belinostat + LEE011 DC8MSF1 LEE011 Metastatic Breast Cancer [13]
Belinostat + Atazanavir DCAM7II Atazanavir Solid Tumor [14]
Belinostat + Vincristine DCLDN0X Vincristine Peripheral T-cell Lymphoma [15]
Carfilzomib + Belinostat DCLIUUB Carfilzomib Non-Hodgkin Lymphoma [16]
MK-1775 + Belinostat DCY1LOX MK-1775 Acute Myeloid Leukemia [17]
Talazoparib + Belinostat DC1DYWZ Talazoparib Metastatic Breast Cancer [18]
Arry-162 + Belinostat DCRIDTP Arry-162 Metastatic Uveal Melanoma [19]
Belinostat + Gemcitabine DC2JB7Q Gemcitabine PTCL [20]
------------------------------------------------------------------------------------
⏷ Show the Full List of 15 DrugCom(s)

References

1 Belinostat FDA Label
2 A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma. Br J Haematol. 2015 Mar;168(6):811-9.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
5 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
6 ClinicalTrials.gov (NCT00878722) Trial of PXD101 (Belinostat) in Combination With Idarubicin to Treat AML Not Suitable for Standard Intensive Therapy
7 ClinicalTrials.gov (NCT00354185) PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma
8 ClinicalTrials.gov (NCT01075425) Belinostat and Bortezomib in Treating Patients With Relapsed or Refractory Acute Leukemia or Myelodysplastic Syndrome
9 ClinicalTrials.gov (NCT00993616) Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin
10 ClinicalTrials.gov (NCT00348985) PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas
11 ClinicalTrials.gov (NCT00351975) Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases
12 ClinicalTrials.gov (NCT05627245) Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment
13 ClinicalTrials.gov (NCT04315233) Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics
14 ClinicalTrials.gov (NCT04184869) Extension Study for Patients Who Had Not Met Criteria for Discontinuation in Previous Sponsored Belinostat Trials
15 ClinicalTrials.gov (NCT01839097) Phase 1 Dose Finding Study of Belinostat for Treatment of Patients With Peripheral T-cell Lymphoma (PTCL)
16 ClinicalTrials.gov (NCT02142530) Carfilzomib Plus Belinostat in Relapsed/Refractory NHL
17 ClinicalTrials.gov (NCT02381548) Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia
18 ClinicalTrials.gov (NCT04703920) Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer
19 ClinicalTrials.gov (NCT05170334) Binimetinib Plus Belinostat for Subjects With Metastatic Uveal Melanoma
20 ClinicalTrials.gov (NCT04747236) Randomized Phase IIB Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCL